Hengrui Pharmaceuticals (600276.SH)'s subsidiary, HRS-2129 tablet, has received the approval notice for clinical drug trials.

Zhichong Finance and Economics APP News, Hengrui Medicine (600276.SH) announced that recently, the company's subsidiaries Shandong Shengdi Pharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. have received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration (referred to as the "NMPA") for HRS-2129 tablets, and will soon conduct clinical trials.